Last week, readers were most interested in a story about Achieve Diagnostics buying the pharmacogenomic assets of H&M Molecular Diagnostics.
The firm currently offers its HerResolve multiomic test for endometriosis that looks at seven biomarkers, including microRNAs ...
The company will conduct a prospective, multicenter study enrolling approximately 954 men with elevated PSA levels who are scheduled for a prostate biopsy.
The planned trial will investigate Eledon's tegoprubart, a therapy designed to prevent organ rejection in kidney transplantation.
The agency cleared more than a dozen assays and instruments for microbiology, molecular biology, clinical chemistry, and other testing.
Verici Dx said on Wednesday that its Tutivia lab-developed test for acute kidney transplant rejection risk has been approved by the New York State Department of Health (NYSDOH). With the approval ...
The Germany-based company is developing a handheld infectious disease testing platform that does not require electricity.
NEW YORK — Diagnostics developer BioAffinity said on Wednesday that it has priced a $3.2 million public stock offering. According to the San Antonio-based firm, it intends to sell 4 million shares of ...
The guidelines state that a test must be FDA-approved, personalized, tumor-informed, multiplex, and use PCR-NGS for ctDNA.
NEW YORK – Alzheimer's diagnostic company Alzpath announced on Wednesday that it has signed a global licensing agreement with Abbott to develop blood-based tests for Alzheimer's disease. Financial and ...
Last week, readers were most interested in a story about an allegation that Invitae illegally shared patients' genetic data.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results